The Telegraph 2 September 2020 - Associated Press
© 2020 Getty Images NITEROI, BRAZIL - AUGUST 26: A laboratory technician holds a vial of COVID-19 serum made from horse plasma at the Vital Brazil Laboratory on August 26, 2020 in Niteroi, Brazil. The Instituto Vital Brazil started the production of serums for COVID-19 using a technique that separates blood plasma from horses. The institute found that the horse's antibodies had a response 20 to 50 times more potent against the new coronavirus than the plasmas of people who had been infected. The National Health Surveillance Agency (Anvisa) has not yet released the serum for testing. (Photo by Luis Alvarenga/Getty Images)
Antibodies that people make to fight coronavirus last for at least four months after diagnosis and do not fade quickly as some earlier reports suggested, scientists have found.
Tuesday's report, from tests on more than 30,000 people in Iceland, is the most extensive work yet on the immune system's response to the virus over time, and is good news for efforts to develop vaccines.
If a vaccine can spur production of long-lasting antibodies as natural infection seems to do, it gives hope that "immunity to this unpredictable and highly contagious virus may not be fleeting", scientists from Harvard University and the US National Institutes of Health wrote in a commentary published with the study in the New England Journal of Medicine.
One of the big mysteries of the pandemic is whether having had coronavirus helps protect against future infection, and for how long. Some smaller studies previously suggested that antibodies may disappear quickly and that some people with few or no symptoms may not make many at all.
The new study was done by Reykjavik-based deCODE Genetics, a subsidiary of the US biotech company Amgen, with several hospitals, universities and health officials in Iceland.
The country has tested 15 per cent of its population since late February, when its first Covid-19 cases were detected, giving a solid base for comparisons.
Scientists used two types of coronavirus testing: the kind from nose swabs or other samples that detect bits of the virus, indicating infection; and tests that measure antibodies in the blood, which can show whether someone was infected now or in the past.
Blood samples were analysed from 30,576 people using various methods, and someone was counted as a case if at least two of the antibody tests were positive. These included a range of people, from those without symptoms to people hospitalised with signs of Covid.
In a subgroup that tested positive, further testing found that antibodies rose for two months after their infection initially was diagnosed and then plateaued and remained stable for four months.
Previous studies suggesting that antibodies faded quickly may have been just looking at the first wave of antibodies the immune system makes in response to infection; those studies mostly looked 28 days after diagnosis. A second wave of antibodies forms after a month or two into infection, and this seems more stable and long-lasting, the researchers report.
The results do not necessarily mean that all countries' populations will be the same, or that every person has this sort of response. Other scientists recently documented at least two cases where people seem to have been reinfected with coronavirus months after their first bout.
The new study does not establish how much or which type of antibody confers immunity or protection - that remains unknown.
The study also found:
- Testing through the bits-of-virus method that is commonly done in community settings missed nearly half of people who were found to have had the virus by blood antibody testing. That means the blood tests are far more reliable and better for tracking the spread of the disease in a region and for guiding decisions and returning to work or school, researchers say.
- Nearly a third of infections were in people who reported no symptoms.
- Nearly one per cent of Iceland's population was infected in this first wave of the pandemic, meaning the other 99 per cent are still vulnerable to the virus.
- The infection fatality rate was 0.3 per cent. That is about three times the fatality rate of seasonal flu and in keeping with some other more recent estimates, said Dr Derek Angus, critical care chief at the University of Pittsburgh Medical Centre.
Although many studies have been reporting death rates based on specific groups such as hospitalised patients, the rate of death among all infected with coronavirus has been unknown.
The news that natural antibodies do not quickly disappear "will be encouraging for people working on vaccines", Dr Angus said.
Kayıtlar
0 Comments:
Yorum Gönder